Next Phase Newsletter

A venture capital firm based in Michigan, USA is investing exclusively in early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities.

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP.

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm backed by a China-based investment group was founded in 2017 and is based in San Francisco, CA. The firm closed its inaugural fund of $300M and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest $15-20M over the life of the company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest mainly in USA-based companies but may invest up to 20% of the fund in companies based in Western Europe.

The firm is focused solely on early-stage therapeutics and will not consider opportunities in medical devices, diagnostics, healthcare services or healthcare IT. The firm is primarily interested in traditional therapeutic modalities – programs that aim to discover and develop small molecule, antibody/protein-based clinical candidates will be considered. The ideal stages of development would be anywhere from IND candidate (12-24 months from the clinic) through Phase I, and the firm is open to all indications including orphan and rare diseases.

The firm can work with all types of management teams and places more importance on their technology. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A leading global insurance company based in the UK launched a corporate venture capital arm in 2015. The fund will invest £100M over the next 3-5 years and will generally allocate £1-5M for up to 20% equity stake, and selectively does convertible financing as well. The firm does not invest strictly for financial returns and seeks a strategic relationship with the companies they invest in. The firm will typically participate in Series A and B rounds. The firm anticipates 4-5 investments per year, although this number is subject to fluctuate depending on deal flow. The firm will invest in technologies that will impact regions where the parent company has a footprint.

In the life sciences space, the firm seeks innovative technologies that can disrupt and transform the future of insurance. The firm will not consider therapeutics or biopharma opportunities. Any technology with implications to the insurance industry will be considered, including smart diagnostics, genomics, etc. The firm has expressed interest in technology that helps with chronic disease management and considered telemedicine companies as well. In terms of diagnostics, the firm expects the technology to be undergoing promising clinical trials that contribute to its validation. For companies that fall into the healthcare IT sector, the firm expects some ongoing traction and key partnerships to be in place.

The firm seeks to work with companies backed by a full management team with strong industry expertise. Ideally, the team will have a strong life sciences background and an experienced advisory team, with good understanding of how their product or technology works. The firm can act as the lead or co-investor and will most likely take a board seat if they were to lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global innovation incubator and investment group based in San Francisco, CA focuses on biomedical R&D technologies and therapeutics. In addition to an incubator for early-stage life science companies, the group has assembled a senior team of investors and executives and had their first close of a new, early-stage venture fund at $80M and is expecting a second close at $200M in Q2 of 2018. The firm will invest in seed and series A rounds in companies in the U.S. and China, and targets initial investments of up to $5M. The firm usually participates as a co-investor in a syndicate, but going forward looks to lead more priced financing rounds. The group is flexible with deal structures and may employ convertibles, straight equity, etc. depending on the needs of the company.

The firm is primarily focused on therapeutics and research tools (ex. CRISPR) and is open to most modalities, but has the most interest and expertise in antibodies and immune modulator drugs. As for therapeutic areas, the group is most interested in oncology and cognitive disorders, but will also consider therapeutics in other indications and looks to broaden their portfolio going forward.

The firm has no strict requirements for companies or management teams and is comfortable working with first-time or novice entrepreneurs as the firm’s leadership team has deep experience in the life sciences space and looks to provide guidance and strategic direction to portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2016 with headquarters in Germany makes 2-4 equity investments in the range from $1-5M per year. The firm has completed their fundraising in April 2017 and is actively seeking new investments globally, with a focus in USA and Europe.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm will consider companies working in therapeutics, diagnostics, nutritional products and advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, the firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in Australia focuses on late stage therapeutics. The firm manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Middle East, and Australia.

The firm is currently looking for new investment opportunities in therapeutics space. The firm is only interested in later stage technology at Phase II or later. The firm is open to all subsectors and indications in therapeutics, though is not interested in lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials (Phase II or later) with human data or on-the-market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com